title: Intracameral cefuroxime: prophylaxis of postoperative endophthalmitis after cataract surgery.
abstract: Results of the landmark European Society of Cataract and Refractive Surgeons trial and additional prospective and retrospective studies support the use of intracameral cefuroxime in the prophylaxis of endophthalmitis following cataract surgery. Prophylaxis with intracameral cefuroxime at the recommended dose appears to be well tolerated in patients undergoing cataract surgery. However, off-label use of intracameral cefuroxime usually requires a two-step dilution process with the potential for dilution errors, and there are also concerns regarding the risk of contamination. Aprokam® (intracameral cefuroxime) has been approved in the EU for the prophylaxis of postoperative endophthalmitis after cataract surgery. After reconstitution of Aprokam®, no further dilution is required and each vial is only indicated for single-patient use; this has the potential to reduce the risk of both dilution errors and contamination.
authors: Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. DRU@adis.com
authors: Gillian M
authors: GM
authors: Keating
mesh_terms: D000867:Anterior Chamber / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D002387:Cataract Extraction; D002444:Cefuroxime / Q000627:therapeutic use*; D009877:Endophthalmitis / Q000517:prevention & control*; D015818:Eye Infections, Bacterial / Q000517:prevention & control*; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D002444:Cefuroxime